Seroatlas · Human Serome Atlas

DLL3

Delta-like protein 3

Also known as: DLL3_HUMAN, SCDO1

Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene

Protein identityUniProt · HPA

UniProt accession
Q9NYJ7
Gene
DLL3
Ensembl
ENSG00000090932
Chromosome
19
Canonical length
618 aa
Protein class
Disease related genes, Human disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins
Subcellular location
Nucleoplasm,Golgi apparatus,Plasma membrane

OverviewNCBI Gene

This gene encodes a member of the delta protein ligand family. This family functions as Notch ligands that are characterized by a DSL domain, EGF repeats, and a transmembrane domain. Mutations in this gene cause autosomal recessive spondylocostal dysostosis 1. Two transcript variants encoding distinct isoforms have been identified for this gene. [provided by RefSeq, Jul 2008]

Canonical amino-acid sequenceUniProt

618 residues, UniProt reviewed canonical sequence.

>Q9NYJ7|DLL3
     1  MVSPRMSGLL SQTVILALIF LPQTRPAGVF ELQIHSFGPG PGPGAPRSPC SARLPCRLFF
    61  RVCLKPGLSE EAAESPCALG AALSARGPVY TEQPGAPAPD LPLPDGLLQV PFRDAWPGTF
   121  SFIIETWREE LGDQIGGPAW SLLARVAGRR RLAAGGPWAR DIQRAGAWEL RFSYRARCEP
   181  PAVGTACTRL CRPRSAPSRC GPGLRPCAPL EDECEAPLVC RAGCSPEHGF CEQPGECRCL
   241  EGWTGPLCTV PVSTSSCLSP RGPSSATTGC LVPGPGPCDG NPCANGGSCS ETPRSFECTC
   301  PRGFYGLRCE VSGVTCADGP CFNGGLCVGG ADPDSAYICH CPPGFQGSNC EKRVDRCSLQ
   361  PCRNGGLCLD LGHALRCRCR AGFAGPRCEH DLDDCAGRAC ANGGTCVEGG GAHRCSCALG
   421  FGGRDCRERA DPCAARPCAH GGRCYAHFSG LVCACAPGYM GARCEFPVHP DGASALPAAP
   481  PGLRPGDPQR YLLPPALGLL VAAGVAGAAL LLVHVRRRGH SQDAGSRLLA GTPEPSVHAL
   541  PDALNNLRTQ EGSGDGPSSS VDWNRPEDVD PQGIYVISAP SIYAREVATP LFPPLHTGRA
   601  GQRQHLLFPY PSSILSVK

LocalizationUniProt · AlphaFold · HPA

Whether an antibody against DLL3 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.

Antibody reachability
Cell surface
Secreted
No
Transmembrane segments
1
Mean surface accessibility (rSASA)
0.46
Highest tissue expression
27 nTPM

Expression across tissuesHPA

Tissue

  • cerebral cortex: 27 nTPM
  • basal ganglia: 11 nTPM
  • amygdala: 11 nTPM
  • hypothalamus: 8.3 nTPM
  • hippocampal formation: 7.9 nTPM
  • midbrain: 5.8 nTPM

Single-cell type

  • oocytes: 97 nCPM
  • oligodendrocyte progenitor cells: 49 nCPM
  • differentiating spermatogonia: 46 nCPM
  • undifferentiated spermatogonia: 27 nCPM
  • early primary spermatocytes: 17 nCPM
  • epididymal basal cells: 13 nCPM

Immune cell

  • memory B-cell: 2.6 nTPM
  • naive CD8 T-cell: 1.4 nTPM
  • memory CD8 T-cell: 0.5 nTPM
  • naive B-cell: 0.4 nTPM
  • gdT-cell: 0.3 nTPM
  • total PBMC: 0.2 nTPM

Brain region

  • basal ganglia: 7.7 nTPM
  • white matter: 7.2 nTPM
  • cerebral cortex: 6 nTPM
  • medulla oblongata: 6 nTPM
  • amygdala: 5.7 nTPM
  • midbrain: 5.6 nTPM

DiseaseUniProt · ClinVar · IEDB · PubMed

Four sources answering four different questions about DLL3.

Disease | AllUniProt

Conditions DLL3 is implicated in, by any mechanism.

  • Spondylocostal dysostosis 1, autosomal recessive (SCDO1) MIM:277300

Disease | GeneticClinVar

56 pathogenic / likely-pathogenic of 700 ClinVar records.

Conditions with pathogenic or likely-pathogenic variants.

Genetic constraint and essentialitygnomAD · DepMap

Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.

gnomAD LOEUF (loss-of-function intolerance)
0.87
gnomAD pLI
0
gnomAD missense Z
0.33
DepMap mean gene effect
-0.03
DepMap dependency class
selective

Cancer expressionTCGA

Across TCGA tumor cohorts, this protein is over-expressed in roughly 4% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).

OntologyGO

Biological processes

Molecular functions

Cellular components

Protein domainsUniProt · Pfam · InterPro

KeywordsUniProt

Antibody and autoantibody relevanceSeroatlas analysis

Seroatlas reads DLL3 as an antibody target. Whether an autoantibody or antibody against DLL3 could matter depends on whether native DLL3 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.

DLL3 is annotated at the cell surface, where native DLL3 is exposed to circulating antibodies and is a prime autoantibody target that could block, deplete, or overstimulate it.

Annotation status

The present source text does not explicitly label DLL3 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.

Canonical record: https://seroatlas.com/gene/DLL3. Study-independent annotations aggregated from UniProt, Human Protein Atlas, PubMed, IEDB, Pfam, InterPro, Gene Ontology, AlphaFold, gnomAD, DepMap, ClinVar, TCGA. Catalog release seroatlas-reviewed-human-uniprot-20260313.

Seroatlas is the reference for exploring autoantibody and antibody serology at the human-protein level: the autoreactome and human serome, multiplex serology (HuProt, HuScan, VirScan, PhIP-Seq).

© 2026 · Seroatlas, Discover Oregon LLC · Terms of use

Loading the interactive Seroatlas protein explorer...